Brussels, 30/11/2009 (Agence Europe) - Pointing out that many patients suffering from rare diseases do not have access to the orphan drugs which could save their lives, EURORDIS, the organisation representing such patients at European level, has just sent the European Commission a range of proposals to reduce delays in effective marketing and reimbursement of new treatments. In line with experts on the area of orphan drugs and with the industry, EURORDIS proposes that, within the European...